Big Pharma M&A Accelerates as Patent Expiries Drive Urgent Dealmaking
Biotech mergers and acquisitions (M&A) are set for a significant surge in 2026, as major pharmaceutical companies aggressively pursue acquisitions to enhance their product pipelines in anticipation of impending patent expirations. This trend is not merely a rebound from the COVID-19 pandemic years; it reflects a broader and more sustainable shift in the industry, according to insights from multiple analysts and investors.
In the first quarter of 2026, the total value of biotech M&A reached $84 billion, a notable increase from $44.4 billion during the same period last year. This marks the strongest start to a year since 2019, when total deals amounted to $147.7 billion, as reported by Dealogic.
Factors Driving the Surge
The urgency surrounding patent expirations is a key factor driving this M&A activity. However, experts also point to several other contributing elements. Deep cash reserves, attractive valuations in the biotech sector, a wave of newly approved drugs, and increasing confidence in navigating regulatory challenges are all fueling this trend.
If the current pace continues, the total biopharma M&A value for 2026 could surpass $250 billion, positioning it as the second-highest year on record, following 2019’s total of $328 billion, which included significant mergers like Bristol Myers Squibb’s acquisition of Celgene.
Patrice Mesnier, founding partner at Oldenburg Capital Partners, noted that the combination of strategic urgency, tighter private funding, and an uncertain IPO market has created an environment conducive to accelerated dealmaking.
The Patent Cliff
Pharmaceutical companies are approaching critical patent cliffs for several of their leading products. Merck’s Keytruda, a cancer treatment that accounts for over half of the company’s revenue, is set to lose its exclusivity in 2028. Other major players, including Eli Lilly, Gilead, Bristol Myers Squibb, and Pfizer, are also facing similar challenges with their blockbuster drugs.
Eason Hahm, director of biopharma investment banking at William Blair, estimates that over $300 billion in revenue within the sector will face loss of exclusivity (LOE) within the next five years. Bill Holodnak, founder of advisory firm Occam Global, indicated that buyers are motivated by anxiety over their diminishing portfolios, emphasizing the industry’s need to adapt to the reality of generic competition.
Financial Strength Fuels Acquisitions
Strong balance sheets are enabling pharmaceutical companies to act decisively. Eli Lilly, for instance, concluded 2025 with over $7.27 billion in cash and equivalents, facilitating board-level justifications for acquisitions. The company has already spent more than $35 billion on acquisitions as of April 29, 2026.
Eli Lilly, Gilead Sciences, and Merck have emerged as the most active acquirers this year. Mesnier remarked that large pharmaceutical companies can no longer afford to wait years to build internal pipelines; instead, they are focused on acquiring time through strategic purchases.
Mid-Size Deals on the Rise
Recent leadership changes at companies like GSK and Novo Nordisk have coincided with a more aggressive approach to M&A. Shifts in senior development and strategy roles at firms such as Bristol Myers Squibb, Gilead, and AbbVie have also impacted the dynamics of deal negotiations and risk assessment.
Analysts from Bernstein highlighted that the future global revenue exposed to patent expirations over the next seven years is approximately 2.5 times higher than in the previous 16 years, creating a sustained urgency for dealmaking.
Emily Oldshue, a partner at Ropes & Gray law firm, noted that there is a growing appetite for M&A, particularly in the sub-$10 billion range. Companies are increasingly willing to take risks and are employing various structures to hedge and spread those risks.
Focus on Oncology and Emerging Technologies
Oncology continues to be a primary focus for big pharma in terms of dealmaking, alongside strong interests in immunology, neurology, cardiovascular diseases, and obesity. Successful drugs in these areas can generate substantial revenues to counterbalance impending patent losses.
Additionally, companies leveraging artificial intelligence and machine learning to expedite drug discovery and enhance clinical development are becoming increasingly attractive targets. Mark Kvamme, CEO of the O.H.I.O. Fund, emphasized that AI technologies are enabling faster development timelines for new therapies.
For more insights, visit Zawya.
Read all the latest developments and breaking updates in the Latest News section.
Published on 2026-05-01 19:09:00 • By the Editorial Desk
